EVO Evotec SE IFRS Annual reports only
Pharmaceutical Preparations · Nasdaq · SEC CIK 1412558 · Reporting currency EUR · Fiscal year ends 12/31
Financial factors as of 2024-12-31 (FY2024), by fiscal year; growth vs the previous fiscal year
Growth
Margins
Returns
Leverage & solvency
Cash quality & payout
Factor history charts and full statement history on Pro 🔒
Financial statements
| Unit: EUR | FY2024*2024-12-31 | FY2023*2023-12-31 | FY20222022-12-31 | FY20212021-12-31 | FY20202020-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | 796.97M | 781.43M | 751.45M | 618.03M | 500.92M |
| Cost of revenue | 682.09M | 606.38M | 577.38M | 466.49M | 375.18M |
| Gross profit | 114.88M | 175.05M | 174.06M | 151.54M | 125.74M |
| R&D expense | 50.86M | 68.53M | 76.64M | 72.20M | 63.95M |
| SG&A expense | 188.20M | 169.61M | 156.19M | 105.44M | 77.20M |
| Operating income | -142.52M | -47.51M | 20.85M | 41.00M | 48.56M |
| Interest expense | — | — | 13.15M | 9.25M | 8.46M |
| Pretax income | -193.98M | -80.59M | -153.96M | 236.98M | 25.84M |
| Income tax | 2.10M | 3.32M | 21.70M | 21.47M | 19.56M |
| Net income | -196.08M | -83.91M | -175.66M | 215.51M | 6.28M |
| EBITDA | -40.90M | 45.47M | 104.05M | 111.39M | — |
| EPS (basic) | -1.11 | -0.47 | -0.99 | 1.30 | 0.04 |
| EPS (diluted) | -1.11 | -0.47 | -0.99 | 1.30 | 0.04 |
| Balance sheet | |||||
| Cash & equivalents | 306.39M | 510.91M | 415.15M | 699.33M | 422.58M |
| Short-term investments | 90.41M | 93.20M | 303.33M | 158.91M | 59.35M |
| Receivables | 116.32M | 98.40M | 171.80M | 132.08M | 79.00M |
| Inventory | 31.12M | 30.89M | 29.82M | 25.79M | 13.59M |
| Current assets | 681.96M | 903.16M | 1.07B | 1.10B | 658.84M |
| PP&E, netmay include right-of-use assets (IFRS) | 823.94M | 806.56M | 650.20M | 484.60M | 337.30M |
| Goodwill | 282.85M | 275.63M | 274.82M | 257.57M | 247.37M |
| Intangibles | 26.44M | 15.45M | 23.82M | 30.85M | 98.04M |
| Total assets | 1.91B | 2.25B | 2.26B | 2.24B | 1.46B |
| Current liabilities | 344.58M | 464.57M | 337.71M | 324.52M | 208.46M |
| Short-term debt | 27.11M | 129.97M | 1.56M | 36.14M | 15.39M |
| Long-term debt | — | — | 328.30M | 326.34M | 331.02M |
| Total debt | — | — | 329.85M | 362.48M | 346.41M |
| Total liabilities | 959.98M | 1.13B | 1.07B | 857.48M | 737.88M |
| Shareholders' equity | 952.52M | 1.12B | 1.19B | 1.38B | 724.46M |
| Net debt | — | — | -85.30M | -336.85M | -76.17M |
| Shares outstanding | 177.55M | 177.19M | 176.95M | 176.61M | 163.91M |
| Cash flow statement | |||||
| Operating cash flow | 18.22M | 36.44M | 205.81M | 126.60M | 44.72M |
| Capital expenditure | 117.47M | 213.32M | 181.35M | 118.94M | 99.07M |
| Free cash flow | -99.25M | -176.88M | 24.46M | 7.66M | -54.35M |
| Investing cash flow | -71.19M | -13.29M | -412.80M | -242.79M | -155.09M |
| Financing cash flow | -161.42M | 71.96M | -58.15M | 393.01M | 246.41M |
| Depreciation & amortization | 101.62M | 92.98M | 83.20M | 70.40M | — |
| Stock-based compensation | 5.04M | 9.63M | 9.92M | 7.80M | 5.29M |
Free plan shows the latest 5 periods; Pro shows all 6 🔒
· This company reports under IFRS: some line items differ from US GAAP — operating income is not required, interest expense may be broader "finance costs", and banks have no standard revenue line.
· This company files only annual reports with the SEC (20-F for foreign issuers), so there is no quarterly data; factors are by fiscal year and growth is vs the previous fiscal year.
· Amounts are in the company's reporting currency, EUR, not USD; the site does no currency conversion.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.